Connect Biopharma (CNTB) Stock Forecast, Price Target & Predictions
CNTB Stock Forecast
Connect Biopharma stock forecast is as follows: an average price target of $1.50 (represents a 20.00% upside from CNTB’s last price of $1.25) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CNTB Price Target
The average price target for Connect Biopharma (CNTB) is $1.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential 20.00% upside from CNTB's last price of $1.25.
CNTB Analyst Ratings
According to 2 Wall Street analysts, Connect Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for CNTB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Connect Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 05, 2022 | Joseph Catanzaro | Piper Sandler | $1.50 | $0.82 | 82.88% | 20.00% |
The latest Connect Biopharma stock forecast, released on May 05, 2022 by Joseph Catanzaro from Piper Sandler, set a price target of $1.50, which represents a 82.88% increase from the stock price at the time of the forecast ($0.82), and a 20.00% increase from CNTB last price ($1.25).
Connect Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.25 | $1.25 | $1.25 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Connect Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Connect Biopharma's last price of $1.25. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Connect Biopharma's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave CNTB a "Buy" rating, the same as its previous rate.
Connect Biopharma Financial Forecast
Connect Biopharma Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | $1.10B | - | $1.06B |
| High Forecast | - | $1.10B | - | $1.06B |
| Low Forecast | - | $1.10B | - | $1.06B |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
Connect Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNTB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Connect Biopharma EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict CNTB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Connect Biopharma's previous annual EBITDA (undefined) of $NaN.
Connect Biopharma Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $606.40K | $-80.66K | $627.83K | $-88.92K |
| High Forecast | $606.40K | $-80.66K | $627.83K | $-88.92K |
| Low Forecast | $606.40K | $-80.66K | $627.83K | $-88.92K |
| Surprise % | - | - | - | - |
Connect Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNTB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Connect Biopharma SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
Connect Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNTB last annual SG&A of $NaN (undefined).
Connect Biopharma EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $11.01 | $-1.46 | $11.40 | $-1.61 |
| High Forecast | $11.01 | $-1.46 | $11.40 | $-1.61 |
| Low Forecast | $11.01 | $-1.46 | $11.40 | $-1.61 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Connect Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNTB previous annual EPS of $NaN (undefined).
Connect Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics | $1.02 | $7.33 | 618.63% | Buy |
| CTMX | CytomX Therapeutics | $1.20 | $5.77 | 380.83% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $2.79 | $7.00 | 150.90% | Buy |
| NXTC | NextCure | $1.42 | $3.00 | 111.27% | Buy |
| CNTB | Connect Biopharma | $1.25 | $1.50 | 20.00% | Buy |
| TIL | Instil Bio | $14.25 | $6.50 | -54.39% | Hold |
CNTB Forecast FAQ
Is Connect Biopharma a good buy?
Yes, according to 2 Wall Street analysts, Connect Biopharma (CNTB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CNTB's total ratings.
What is CNTB's price target?
Connect Biopharma (CNTB) average price target is $1.5 with a range of $1.5 to $1.5, implying a 20.00% from its last price of $1.25. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Connect Biopharma stock go up soon?
According to Wall Street analysts' prediction for CNTB stock, the company can go up by 20.00% (from the last price of $1.25 to the average price target of $1.5), up by 20.00% based on the highest stock price target, and up by 20.00% based on the lowest stock price target.
Can Connect Biopharma stock reach $2?
CNTB's average twelve months analyst stock price target of $1.5 does not support the claim that Connect Biopharma can reach $2 in the near future.
What are Connect Biopharma's analysts' financial forecasts?
CNTB's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $1.06B (high $1.06B, low $1.06B), average EBITDA is $0 (high $0, low $0), average net income is $-88.923K (high $-88.923K, low $-88.923K), average SG&A $0 (high $0, low $0), and average EPS is $-1.614 (high $-1.614, low $-1.614).